![Kaplan-Meier estimates of (A) progression-free survival (PFS) and (B) overall survival (OS) for patients with diffuse large B-cell lymphoma without MYC rearrangement (MYC-negative), patients with MYC single hit (SH; immunoglobulin [IG]), MYC-SH (non-IG), MYC double hit/triple hit (DH/TH; IG), or MYC-DH/TH (non-IG). Reprinted with permission. © 2019 American Society of Clinical Oncology. All rights reserved. From Rosenwald, A et al: J Clin Oncol 37 (35), 2019: 3359-3368.](https://ash.silverchair-cdn.com/ash/content_public/journal/thehematologist/17/2/10.1182_hem.v17.2.10279/5/e3bbf4d2-4877-4b7e-8ac9-9b3acf16e8c8.jpeg?Expires=1724269553&Signature=yku5M3GKAmcZB9lCKyGuUDreqyhfn2gM2eVBghWbOIYUTON~j~OnOnM8Y1rmY9FCx8HL4ArBt3-TKRndAb37j6N4DifspLpuu7yaQfqFNFMv8r2ZdBH35teEptfSMDpg5cEMPi3F9aLMGBePzQDBbZO3zekF0fk14dC-d96yAssxvsu8ADNjRrYH7Q66q5jG-HnpLEAvyPxAv7tyGfixvbd58m0PHuHbIOWiJ6RlWJmoEZHjWYHxNaZYxqnF3F-URuyJL5qK0gxMd0yIkdm2bw09YZSb7DloctuObRT5YJclix4HvGJHAxRr2Ss3EbzZ-YpyCu1E8Opomoriy2FKKQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Kaplan-Meier estimates of (A) progression-free survival (PFS) and (B) overall survival (OS) for patients with diffuse large B-cell lymphoma without MYC rearrangement (MYC-negative), patients with MYC single hit (SH; immunoglobulin [IG]), MYC-SH (non-IG), MYC double hit/triple hit (DH/TH; IG), or MYC-DH/TH (non-IG). Reprinted with permission. © 2019 American Society of Clinical Oncology. All rights reserved. From Rosenwald, A et al: J Clin Oncol 37 (35), 2019: 3359-3368.
